A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Topiramate YL Study Group.
about
Greater response to placebo in children than in adults: a systematic review and meta-analysis in drug-resistant partial epilepsyTopiramate monotherapy for juvenile myoclonic epilepsyPharmacological interventions for epilepsy in people with intellectual disabilitiesTreatment of Lennox-Gastaut syndromeTopiramate monotherapy for juvenile myoclonic epilepsyTreatment of Lennox-Gastaut syndromePharmacological interventions for epilepsy in people with intellectual disabilitiesTreatment of Lennox-Gastaut syndromeAntiepileptic Drug Treatment in Children with EpilepsyThe Role of Topiramate in the Management of Cocaine Addiction: a Possible Therapeutic OptionThe promise of new antiepileptic drugs.Long-term control of epileptic drop attacks with the combination of valproate, lamotrigine, and a benzodiazepine: a 'proof of concept,' open label study.Efficacy and tolerability of the new antiepileptic drugs, II: Treatment of refractory epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society.Catastrophic epilepsy in childhood.Rational approach to treatment options for Lennox-Gastaut syndrome.Epilepsy and intellectual disability.Anticonvulsant blood levels: historical review with a pediatric focus.Is refractory epilepsy preventable?Pharmacokinetics and pharmacodynamics of topiramate.Treating Lennox-Gastaut syndrome in epileptic pediatric patients with third-generation rufinamide.Beneficial and adverse psychotropic effects of antiepileptic drugs in patients with epilepsy: a summary of prevalence, underlying mechanisms and data limitations.New generation anticonvulsants for the treatment of epilepsy in children.Appropriate use of medications for seizures. Guiding principles on the path of efficacy.Clinical pharmacology and therapeutic use of the new antiepileptic drugs.A revisited strategy for antiepileptic drug development in children: designing an initial exploratory step.Advances in our understanding of early childhood epilepsies: 1999-2000.Lennox-Gastaut syndrome.Antiepileptic drug selection in pediatric epilepsy.Infantile spasms and Lennox-Gastaut syndrome.Adjunctive rufinamide in Lennox-Gastaut syndrome: a long-term, open-label extension study.Drug treatment of epilepsy in the century of the ILAE: the second 50 years, 1959-2009.Efficacy of topiramate in migraine prophylaxis: a retrospective chart analysis.Treatment options for epileptic myoclonus and epilepsy syndromes associated with myoclonus.Clinical experience with open-label topiramate use in infants younger than 2 years of age.Antiepileptic drug development for "therapeutic orphans".Treatment strategies for myoclonic seizures and epilepsy syndromes with myoclonic seizures.Short term outcomes of topiramate monotherapy as a first-line treatment in newly diagnosed West syndrome.Pharmacologic treatment of the catastrophic epilepsies.Behavioral and psychiatric adverse events associated with antiepileptic drugs commonly used in pediatric patients.Management of epilepsy in mentally retarded children using the newer antiepileptic drugs, vagus nerve stimulation, and surgery.
P2860
Q21563404-57A8D4B9-3153-4341-949E-E1136A7F4AB7Q24186962-A350611A-7BC2-48B7-A6CF-AA0C9D6AB198Q24187353-5CED29D5-6987-425C-995A-AA7106F0590AQ24200686-CBB002D4-6BF2-4B52-90F6-56A13584A114Q24201882-4CD17F2B-15AB-4E28-8AE5-6C7B49612E76Q24239970-15C4C92B-C7CC-4684-BCE0-1DC8E4BAEC69Q24244246-6957BF55-7EBA-48D0-AC60-F90BD28747BDQ24248017-E7DA3CFE-8BCD-4341-A808-9A34B1E7BFB1Q26781771-5610E0DA-522E-4B11-962E-610C508D44C9Q28082830-8E3FD009-EB7E-4484-95AF-6653466E3A4BQ30674774-9B2542FF-B304-4F87-AFB0-3524F72A1320Q33160210-757F7160-05E4-4D21-9DB8-D0FF02B3F442Q33202111-FFF998E9-921A-46CC-A047-4624103876B8Q33961498-C723B5E2-3282-43D6-9D49-381FA368B65DQ33971818-7EE848EF-0A42-48D1-AA3A-FDDB626CA949Q34083161-0D9BA95D-9A7E-4CE0-A820-8797F9B925EFQ34099870-3DA11CD4-A91C-4B91-8498-5A8F2BC02473Q34123660-7EA1192A-408D-420D-9FBB-DB6D2C010086Q34161725-150F3FDF-0C75-4DFB-932C-8713389312E4Q34184171-967C96B4-C8BF-41DE-B72A-B3B0F0CD13E4Q34186198-B080C358-55EF-46F1-8D35-23D24D4EB9C0Q34504288-3802CF24-A77A-4C22-9317-5D9CC3C9FCDDQ34505848-8C2D7026-9A6A-4DF8-9F61-D06D6B5DAEE2Q34541736-5E111BE1-7C6B-4B48-A910-AE26DA3B4716Q34560399-56A879B6-D89C-4057-BAE8-A6FADD72DBA3Q34566532-1DE9DF72-7B13-4225-9EA4-5AFDF0EB345BQ34579471-8D62B926-2DCC-4EA0-A58F-F74C92D352FEQ34599666-A5355026-68EA-459E-87FA-8D54E77E0FA9Q34599704-13B2C99E-F126-44DA-9623-2457AE018EC5Q34617378-BDD326EA-25CA-43ED-9EEB-FFECD2043112Q34965263-0F24B710-F858-4D99-B960-56B27DD7ED16Q34976048-6A5E9E59-7C62-4953-BA51-8C28D0AE31CEQ34986819-B6DB73D7-D870-4FE3-B428-4968EFA8043EQ35132987-5375F955-944B-40C1-A8BE-4E087F5B7F17Q35200123-0888225B-0C7E-412B-84DA-94FC18D557C3Q35594589-2AEFAF95-AAD0-4F05-A5AA-8D6A494BD717Q35649274-C7BB3BB4-DE99-4892-9F50-41C964AB2C01Q35850450-5B820BF4-914D-480A-9332-0AB679F73A53Q35939591-0830F2E8-2EFA-4AE9-82E2-BA8267813B07Q35939608-10F7039E-9CC6-400D-87A1-3ACA8BA44A2E
P2860
A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Topiramate YL Study Group.
description
1999 nî lūn-bûn
@nan
1999 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
A double-blind, randomized tri ...... me. Topiramate YL Study Group.
@ast
A double-blind, randomized tri ...... me. Topiramate YL Study Group.
@en
type
label
A double-blind, randomized tri ...... me. Topiramate YL Study Group.
@ast
A double-blind, randomized tri ...... me. Topiramate YL Study Group.
@en
prefLabel
A double-blind, randomized tri ...... me. Topiramate YL Study Group.
@ast
A double-blind, randomized tri ...... me. Topiramate YL Study Group.
@en
P2093
P356
P1433
P1476
A double-blind, randomized tri ...... me. Topiramate YL Study Group.
@en
P2093
P304
P356
10.1212/WNL.52.9.1882
P407
P577
1999-06-01T00:00:00Z